Skip to content

A Clinical Study of the Transition of Children from ‘Artisanal’ Cannabidiol to Epidiolex (CANN-SWITCH)

This study is for children aged between 2 and 18 years who have Lennox-Gastaut Syndrome or Dravet Syndrome taking artisanal CBD to take part in a 20-week long clinical research study. The primary purpose is to investigate the best way to transition these children from artisanal CBD to a pharmaceutical-grade version of CBD called Epidiolex.

null

Participation Requirements

  • Sex:

    Male, Female

  • Eligible Ages:

    2 to 18

Participation Criteria

Inclusion Criteria:
You or your child may be eligible to participate in this trial if you or your child:

1. Is 2 to 18 years of age, inclusive
2. Has a confirmed clinical diagnosis of Lennox-Gastaut Syndrome or Dravet Syndrome
3. Taking licensed artisanal CBD for seizure control

Doctors will also evaluate other criteria to make sure you and your child qualify for the study.
Exclusion Criteria:
You or your child may not be eligible to participate in this trial if you or your child:

- Is currently pregnant, or breast feeding.
- Has a clinically significant unstable medical condition
- Is currently or has been exposured to Epidiolex
- Currently enrolled in a clinical study

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: REB25-0710